| Document |
Document Title |
|
JP7320852B2 |
A method for continuously processing at least two liquid feed streams is provided. A system for continuously processing at least two liquid feed streams is also provided.
|
|
JP2023533421A |
The present invention relates to a delivery contact lens device for delivering cargo molecules. The device comprises cargo molecules and a nanocomposite comprising hydrophilic polymer domains, hydrophobic polymer domains, aqueous pores, ...
|
|
JP7316214B2 |
The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[
4-(2-pyridinyl)-phenyl]-a...
|
|
JP7312822B2 |
The present invention provides an alginic acid-based injectable hydrogel system for labeling an accurate position of a disease lesion and effectively delivering a drug to a target region. The formulation of the present invention can make...
|
|
JP2023529825A |
[wrap up] Kind Code: A1 Disclosed and described are α-RgIA4 peptide analogs, compositions comprising them, and methods for their treatment and use. For example, an α-RgIA4 peptide analog can include a recognition finger region configur...
|
|
JP2023094485A |
To provide a poultice in which the adhesive force of a paste layer to an adherend is strengthened.A poultice comprises a support layer, a paste layer, and a release liner layer, where the paste layer includes a composition (paste composi...
|
|
JP2023094484A |
To provide a poultice in which the adhesive force of a paste layer to an adherend is strengthened.A poultice comprises a support layer, a paste layer, and a release liner layer, where the paste layer includes a composition (paste composi...
|
|
JP2023528644A |
Antidepressant, amelioration of anxiety and post-traumatic stress syndrome, anesthesia, analgesia, improvement of cognitive function, lung protection, prevention or treatment of amyotrophic lateral sclerosis, or prevention or treatment o...
|
|
JP2023526098A |
According to the present invention, preferably a pharmaceutically acceptable A pharmaceutically acceptable composition is provided in the form of a spray-dried powder comprising a mixture of and a carrier material. The compositions are s...
|
|
JP2023525935A |
The present invention relates to drugs such as analgesics, relaxants, anxiolytics, sedatives, hypnotics, narcotics, anesthetics, and/or other active pharmaceutical ingredients (APIs) having peripheral and/or central nervous effects. It r...
|
|
JP7285790B2 |
It is an object of the present invention to provide an adhesive sheet for skin patch, having adhesive force and cohesive force that are practicable as a pharmaceutical product and exhibiting high drug solubility and sufficient drug skin ...
|
|
JP2023522987A |
According to various aspects of the present disclosure, the present disclosure relates to long-lasting, shelf-stable microsphere formulations of bupivacaine, kits and methods for treating or preventing pain by parenteral injection of mic...
|
|
JP7282736B2 |
The invention provides methods and compositions for treatment of pain, such as joint pain, using capsaicin in a procedure that attenuates transient burning sensation experienced by patients due to capsaicin administration. The methods de...
|
|
JP2023071910A |
To provide pharmaceuticals that are neuroactive and suitable for use as an anesthetic.The present invention is generally directed to neuroactive 19-alkoxy-17-substituted steroids with the structure in the figure and pharmaceutically acce...
|
|
JP2023071871A |
To provide compositions and methods for treating CNS disorders.Neuroactive steroids of the Formula (I) in the figure or a pharmaceutically acceptable salt thereof are used. The compounds are expected to act as GABA modulators. The presen...
|
|
JP7278223B2 |
This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutic...
|
|
JP7276806B2 |
A pharmaceutical composition for treating infertility in a female subject substantially consists of local anesthetic of amide type such as lidocaine, human albumin, viscosity controlling agent selected from recombinant hyaluronic acid an...
|
|
JP2023519536A |
The present invention provides compositions containing at least one N-acetylcysteine and at least one nicotinamide riboside for use in methods of prevention and/or treatment of neurological diseases and/or conditions. In one embodiment o...
|
|
JP7271163B2 |
To provide compositions for external use with favorably suppressed insoluble matter production despite of containing ufenamate and isopropylmethylphenol with water.Compounding (C) lidocaine together with (A) ufenamate and (B) isopropylme...
|
|
JP2023519107A |
T.RegMethods of stimulating or increasing proliferation of cells, T produced by such methodsRegCompositions comprising populations of cells and methods of treating subjects using the compositions are provided herein.
|
|
JP2023518947A |
Sterile ophthalmic gels of chloroprocaine with improved functionality, pharmacokinetics and, in particular, stability with respect to clarity, and methods of making and using same.
|
|
JP2023516952A |
Engineered antibodies are provided that are stable and conjugated to ligands or drugs at ligand/drug to antibody ratios greater than 3, making these conjugates suitable for treatment of a variety of indications. Methods of producing thes...
|
|
JP2023516887A |
A layered drug delivery device comprising a polymeric tissue interface layer and a polymeric backing layer. The polymeric tissue interface layer includes at least one therapeutic agent.
|
|
JP7260250B2 |
To provide an antipruritic patch capable of surely holding a medicine, and improving medicine administration efficiency by solving the problem that a conventional skin external preparation cannot hold a sufficient amount due to that the ...
|
|
JP2023515918A |
The present disclosure relates to sustained release drug delivery systems. In some examples, the composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; ...
|
|
JP7254719B2 |
This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight bi...
|
|
JP2023514434A |
In view of the health and addiction risks associated with opiates, anesthetic emulsions comprising eutectic mixtures of local anesthetics are described herein. In some embodiments, the anesthetic emulsion releases one or more local anest...
|
|
JP2023513175A |
The present invention provides compositions for controlled local deposition of one or more agents within a subject. More specifically, a) a polyethylene glycol (PEG) composition having a first low-molecular-weight PEG (Mw: 200-500 Da) an...
|
|
JP2023041861A |
To provide formulations of nanostructured gels for increased agent loading and adhesion.A gel formulation has been developed which provides high loading, e.g., between about 5% wt./wt. agent/total gel weight and about 50% wt./wt. agent/t...
|
|
JP2023041883A |
To provide a composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases.A composition includes a Chinese herbal compound material or a Chinese herbal compound extract is provided. The ...
|
|
JP7241792B2 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...
|
|
JP2023508293A |
The present invention is a multilayer oral thin film comprising a matrix layer containing at least one polymer and at least one pharmaceutically active agent, and at least one backing layer, wherein at least one backing layer comprises f...
|
|
JP2023027715A |
To suppress the formation of a hydrolysate of an ester-based local anesthetic.A pharmaceutical composition contains (a) an ester-based local anesthetic or a pharmaceutically acceptable salt thereof, and (b) fatty acid glycerol macrogol e...
|
|
JP7225486B2 |
Synthetic amino acid-modified polymers and methods of making the same and using the same are disclosed. The synthetic amino acid-modified polymers possess distinct thermosensitive, improved water-erosion resistant, and enhanced mechanica...
|
|
JP2023022187A |
To provide compositions and methods for treating CNS disorders.Described herein are neuroactive steroids of the formula (II) in the figure or pharmaceutically acceptable salts thereof. Such compounds are supposed, in certain embodiments,...
|
|
JP2023505963A |
Provided is a sustained release pharmaceutical composition comprising a ketamine pamoate salt and a pharmaceutically acceptable carrier thereof. Such compositions include aqueous suspensions, solutions and matrix delivery systems and can...
|
|
JP7215758B2 |
Disclosed is a compound as shown in formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof, or a deuterated derivative thereof. The compo...
|
|
JP2023503581A |
Embodiments include transdermal delivery formulations and methods of transdermal delivery of active agents for systemic distribution. The formulation can be applied to the subject's skin, nails, or hair follicles. After penetrating the s...
|
|
JP7214331B2 |
An object of the present invention is to provide a preparation technology capable of suppressing yellowing of a pharmaceutical composition containing ethyl aminobenzoate and quaternary ammonium salt caused by exposure to light, so as to ...
|
|
JP7213205B2 |
The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparin...
|
|
JP7211974B2 |
A gel formulation has been developed which provides high loading, e.g., between about 5% and about 50% wt/wt agent/total gel weight, of a wide range of agents, especially amine-containing compounds such as local anesthetic agents that ar...
|
|
JP2023009319A |
To provide medicine releasing equipment using light.Medicine releasing equipment includes a light source part and a medicine supply part having a medicine irradiated with light from the light source part. The medicine supply part release...
|
|
JP2023001391A |
To provide a pharmaceutical preparation technique in which a pharmaceutical composition containing ethyl aminobenzoate and quaternary ammonium salt can suppress yellowing generated by light exposure, and be equipped with excellent pharma...
|
|
JP2022554420A |
The present invention provides a stable, non-degradable, edible, inhalable, highly bioavailable pharmaceutical grade ultrafine active pharmaceutical ingredient with 99% purity and 200% increased bioavailability. A soluble, soluble, and d...
|
|
JP2022553929A |
Tumor resection is commonly performed to prevent cancer progression. However, after surgery, there are concerns, including the formation of voids at the surgical site that allow cancer cells to escape, increasing the risk of metastasis. ...
|
|
JP2022553423A |
A ready-to-use injectable composition comprising polymeric microspheres or microparticles of non-animal origin, a hydrogel comprising water and a cellulose derivative gelling agent, and polysorbate 80 is described. Further described are ...
|
|
JP2022553326A |
N-containing derivatives of substituted phenolic hydroxy acid esters, preparation and use are provided. Said compound is as shown in Formula (I). The salt of the compound of formula (I) has good water solubility, can rapidly and complete...
|
|
JP7193072B2 |
To provide pasting materials and patches capable of consecutive attachment for long time even with respect to a bending site such as a joint while being able to be attached and released easily.A patch 10 comprises a base material layer 1...
|
|
JP7187150B2 |
Provided herein are topical ophthalmic preparations which comprise a non-aqueous, self-emulsifying system which can spontaneously give rise to either nanosized emulsions upon contact with an aqueous phase. Also provided herein are method...
|
|
JP7186259B2 |
Described herein are neuroactive steroids of the Formula (II):or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6and------are as defined herein. Such compounds are envisioned, in certain emb...
|
